|
Gene: PUS7L |
Gene summary for PUS7L |
Gene summary. |
Gene information | Species | Human | Gene symbol | PUS7L | Gene ID | 83448 |
Gene name | pseudouridine synthase 7 like | |
Gene Alias | PUS7L | |
Cytomap | 12q12 | |
Gene Type | protein-coding | GO ID | GO:0001522 | UniProtAcc | Q9H0K6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83448 | PUS7L | LZE4T | Human | Esophagus | ESCC | 1.53e-05 | 1.72e-01 | 0.0811 |
83448 | PUS7L | LZE7T | Human | Esophagus | ESCC | 4.53e-09 | 4.50e-01 | 0.0667 |
83448 | PUS7L | LZE22D1 | Human | Esophagus | HGIN | 4.64e-05 | 2.33e-01 | 0.0595 |
83448 | PUS7L | LZE24T | Human | Esophagus | ESCC | 3.18e-15 | 2.51e-01 | 0.0596 |
83448 | PUS7L | P1T-E | Human | Esophagus | ESCC | 1.81e-06 | 3.90e-01 | 0.0875 |
83448 | PUS7L | P2T-E | Human | Esophagus | ESCC | 4.22e-36 | 7.30e-01 | 0.1177 |
83448 | PUS7L | P4T-E | Human | Esophagus | ESCC | 2.45e-40 | 9.21e-01 | 0.1323 |
83448 | PUS7L | P5T-E | Human | Esophagus | ESCC | 1.85e-15 | 2.87e-01 | 0.1327 |
83448 | PUS7L | P8T-E | Human | Esophagus | ESCC | 1.75e-23 | 2.52e-01 | 0.0889 |
83448 | PUS7L | P9T-E | Human | Esophagus | ESCC | 3.56e-05 | 1.15e-01 | 0.1131 |
83448 | PUS7L | P10T-E | Human | Esophagus | ESCC | 3.09e-17 | 3.30e-01 | 0.116 |
83448 | PUS7L | P11T-E | Human | Esophagus | ESCC | 5.37e-04 | 1.67e-01 | 0.1426 |
83448 | PUS7L | P12T-E | Human | Esophagus | ESCC | 5.59e-15 | 2.09e-01 | 0.1122 |
83448 | PUS7L | P15T-E | Human | Esophagus | ESCC | 1.43e-03 | 1.62e-01 | 0.1149 |
83448 | PUS7L | P16T-E | Human | Esophagus | ESCC | 6.39e-18 | 3.16e-01 | 0.1153 |
83448 | PUS7L | P17T-E | Human | Esophagus | ESCC | 2.73e-10 | 3.18e-01 | 0.1278 |
83448 | PUS7L | P20T-E | Human | Esophagus | ESCC | 1.12e-18 | 3.81e-01 | 0.1124 |
83448 | PUS7L | P21T-E | Human | Esophagus | ESCC | 3.85e-19 | 3.84e-01 | 0.1617 |
83448 | PUS7L | P22T-E | Human | Esophagus | ESCC | 3.86e-11 | 1.69e-01 | 0.1236 |
83448 | PUS7L | P23T-E | Human | Esophagus | ESCC | 5.46e-09 | 1.87e-01 | 0.108 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
GO:00015221 | Esophagus | ESCC | pseudouridine synthesis | 16/8552 | 18/18723 | 1.78e-04 | 1.15e-03 | 16 |
GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
GO:0001522 | Oral cavity | OSCC | pseudouridine synthesis | 13/7305 | 18/18723 | 4.45e-03 | 1.79e-02 | 13 |
GO:00015222 | Skin | cSCC | pseudouridine synthesis | 11/4864 | 18/18723 | 1.74e-03 | 1.06e-02 | 11 |
GO:00094513 | Skin | cSCC | RNA modification | 58/4864 | 167/18723 | 7.33e-03 | 3.47e-02 | 58 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PUS7L | SNV | Missense_Mutation | rs774965646 | c.473N>T | p.Pro158Leu | p.P158L | Q9H0K6 | protein_coding | tolerated(0.09) | benign(0) | TCGA-CR-7382-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unspecific | PD | |
PUS7L | SNV | Missense_Mutation | novel | c.1535A>T | p.Glu512Val | p.E512V | Q9H0K6 | protein_coding | tolerated(0.14) | benign(0.243) | TCGA-CV-7423-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PUS7L | SNV | Missense_Mutation | rs139103690 | c.1994C>T | p.Thr665Met | p.T665M | Q9H0K6 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
PUS7L | deletion | Frame_Shift_Del | c.575delA | p.Asn192ThrfsTer6 | p.N192Tfs*6 | Q9H0K6 | protein_coding | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD | |||
PUS7L | deletion | In_Frame_Del | novel | c.53_64delNNNNNNNNNNNN | p.Asn18_Gly22delinsArg | p.N18_G22delinsR | Q9H0K6 | protein_coding | TCGA-YL-A8SA-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 8 | Unknown | Unknown | SD | ||
PUS7L | SNV | Missense_Mutation | c.667N>A | p.Asp223Asn | p.D223N | Q9H0K6 | protein_coding | tolerated(0.09) | benign(0.123) | TCGA-BR-4368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PUS7L | SNV | Missense_Mutation | rs780243371 | c.657N>A | p.Phe219Leu | p.F219L | Q9H0K6 | protein_coding | tolerated(0.12) | benign(0.018) | TCGA-CG-5724-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | PD |
PUS7L | SNV | Missense_Mutation | c.842N>T | p.Arg281Leu | p.R281L | Q9H0K6 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-ET-A39R-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |